Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 10/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NT5C2 | P49902 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546676 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2HTTBRD4NPC1RAB9A | |
| SCHEMBL17372406 | 0.83 | CYP1A2 (0.49) | SMN1; SMN2BRD4TP53HSD17B10TSHR | |
| SCHEMBL9621685 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTBRD4NPC1RAB9A | |
| SCHEMBL11481134 | 0.72 | BRD4 (0.56) | SMN1; SMN2BRD4NPC1RAB9ATP53 | |
| SCHEMBL13656142 | 0.70 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTBRD4NPC1RAB9A | |
| SCHEMBL536913 | 0.70 | BRAF (0.72) | SMN1; SMN2HTTBRD4NPC1RAB9A | |
| SCHEMBL5437612 | 0.70 | BRD4 (0.62) | SMN1; SMN2BRD4NPC1RAB9ATP53 | |
| SCHEMBL17362837 | 0.69 | BRD4 (0.58) | SMN1; SMN2BRD4NPC1RAB9ATP53 | |
| SCHEMBL38663949 | 0.69 | BRD4 (0.58) | SMN1; SMN2HTTBRD4NPC1RAB9A | |
| SCHEMBL7052324 | 0.69 | HDAC1 (0.61) | SMN1; SMN2HTTBRD4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240218399-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024140624-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024134512-A1 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134511-A2 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-06-13 | — | — | US | disclosed |
| EP-3917503-B1 | METHODS OF PREPARING LIPID NANOPARTICLES | MODERNATX INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11969506-B2 | Lipid nanoparticle formulation | MODERNATX, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024084397-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240131150-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SUZHOU ABOGEN BIOSCIENCES CO LTD (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969506-B2 | Lipid nanoparticle formulation | TTPA, SREBF1, SREBF2 | SMN1; SMN2 1929/4885HTT 2334/4885BRD4 3896/4885 |
| US-20240238212-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | SMN1; SMN2 3820/4885HTT 959/4885BRD4 3643/4885 |
| US-20240189408-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | SMN1; SMN2 4431/4885HTT 2363/4885BRD4 2188/4885 |
| US-20240131150-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS | SARS1, POLRMT, SARNP | SMN1; SMN2 2055/4885HTT 629/4885BRD4 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.